Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, peginterferon alfa-2b plus ribavirin therapy in hepatitis C patients was associated with serious adverse drug reactions in 20% of cases, highlighting differences from clinical trial findings.

This report describes a case of alopecia universalis in a woman with hepatitis C linked to pegylated interferon alfa-2b and ribavirin therapy, with hair regrowth observed one year after discontinuation.

In this study, pegylated interferon alfa-2b injections led to local cutaneous reactions, including cutaneous necrosis, in patients with hepatitis C and chronic myelocytic leukemia, requiring dose modifications or treatment withdrawal in some cases.

This case study suggests that treatment with Pil-Food, intended for hair loss prevention, may have triggered postinfantile giant cell hepatitis with autoimmune characteristics, which showed a rapid and effective response to corticosteroid therapy.

This case report documents a reversible instance of complete body hair loss (alopecia universalis) in a patient undergoing chronic hepatitis C treatment with pegylated interferon alpha-2b and ribavirin, with hair regrowth observed within three months after therapy completion.